Pharmaceutical formulations
Provided herein are pharmaceutical formulations comprising a monoacylglycerol lipase (MAGL) inhibitor, or a pharmaceutically acceptable salt thereof, and at least one pharmaceutically acceptable excipient.
1. A pharmaceutical formulation in a solid dosage form comprising:
(a) 1 mg to 60 mg of 1,1,1,3,3,3-hexafluoropropan-2-yl 4-(2-(pyrrolidin-1-yl)-4-(trifluoromethyl)benzyl)piperazine-1-carboxylate, or a pharmaceutically acceptable salt thereof;
(b) 50 mg to 175 mg of microcrystalline cellulose;
(c) 6 mg to 15 mg of croscarmellose sodium; and
(d) 0.5 mg to 2.5 mg of magnesium stearate.
2. The pharmaceutical formulation of claim 1 , wherein the 1,1,1,3,3,3-hexafluoropropan-2-yl 4-(2-(pyrrolidin-1-yl)-4-(trifluoromethyl)benzyl)piperazine-1-carboxylate is a hydrochloride salt.
3. The pharmaceutical formulation in a solid dosage form according to claim 1 comprising:
(a) 2.1 mg of 1,1,1,3,3,3-hexafluoropropan-2-yl 4-(2-(pyrrolidin-1-yl)-4-(trifluoromethyl)benzyl)piperazine-1-carboxylate hydrochloride salt;
(b) 156 mg of microcrystalline cellulose;
(c) 10 mg of croscarmellose sodium; and
(d) 1.7 mg of magnesium stearate.
4. The pharmaceutical formulation in a solid dosage form according to claim 1 comprising:
(a) 10.7 mg of 1,1,1,3,3,3-hexafluoropropan-2-yl 4-(2-(pyrrolidin-1-yl)-4-(trifluoromethyl)benzyl)piperazine-1-carboxylate hydrochloride salt;
(b) 147 mg of microcrystalline cellulose;
(c) 10.2 mg of croscarmellose sodium; and
(d) 1.7 mg of magnesium stearate.
5. The pharmaceutical formulation in a solid dosage form according to claim 1 comprising:
(a) 53.6 mg of 1,1,1,3,3,3-hexafluoropropan-2-yl 4-(2-(pyrrolidin-1-yl)-4-(trifluoromethyl)benzyl)piperazine-1-carboxylate hydrochloride salt;
(b) 104 mg of microcrystalline cellulose;
(c) 10 mg of croscarmellose sodium; and
(d) 1.7 mg of magnesium stearate.
6. The pharmaceutical formulation of claim 1 , wherein the solid dosage form is a tablet.
7. The pharmaceutical formulation of claim 2 , wherein the solid dosage form is a tablet.
8. The pharmaceutical formulation of claim 3 , wherein the solid dosage form is a tablet.
9. The pharmaceutical formulation of claim 4 , wherein the solid dosage form is a tablet.
10. The pharmaceutical formulation of claim 5 , wherein the solid dosage form is a tablet.
11. The pharmaceutical formulation of claim 1 , wherein the solid dosage form is a capsule.
12. The pharmaceutical formulation of claim 2 , wherein the solid dosage form is a capsule.
13. The pharmaceutical formulation of claim 3 , wherein the solid dosage form is a capsule.
14. The pharmaceutical formulation of claim 4 , wherein the solid dosage form is a capsule.
15. The pharmaceutical formulation of claim 5 , wherein the solid dosage form is a capsule.